{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:36:45Z","timestamp":1789011405247,"version":"build-2803163510"},"reference-count":31,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2021,8,24]]},"DOI":"10.1080\/10428194.2021.1913144","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T02:02:45Z","timestamp":1620352965000},"page":"2342-2351","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-na\u00efve chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"62","author":[{"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6983-4028","authenticated-orcid":false,"given":"Claire","family":"Telford","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarang","family":"Abhyankar","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Waweru","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Ringshausen","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0131-2"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510193331606"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15460"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30422-7"},{"key":"CIT0007","unstructured":"NCCN. Clinical Guidelines in Oncology (NCCN Guidelines, 2019) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma version 1.2020 2019. [cited 2020 Sep 10]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx."},{"key":"CIT0008","unstructured":"ESMO. European Society for Medical Oncology eUpdate - Chronic Lymphocytic Leukaemia Treatment Recommendations. 2017. [cited 2020 Jun 22]. Available from: https:\/\/www.esmo.org\/guidelines\/haematological-malignancies\/chronic-lymphocytic-leukaemia\/eupdate-chronic-lymphocytic-leukaemia-treatment-recommendations."},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0779"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0250-9"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169334"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1130"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"CIT0014","unstructured":"USFDA. Project Orbis: FDA approves acalabrutinib for CLL and SLL 2019. [cited 2020 Dec 9]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/project-orbis-fda-approves-acalabrutinib-cll-and-sll#:\u223c:text=On%20November%2021%2C%202019%2C%20the,small%20lymphocytic%20lymphoma%20(SLL)."},{"key":"CIT0015","unstructured":"EMA. Calquence \u2013 SUMMARY OF PRODUCT CHARACTERISTICS 2020; [cited 2020 Dec 9]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/calquence-epar-product-information_en.pdf."},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.2165\/11538370-000000000-00000"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192328"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128404"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"CIT0028","unstructured":"Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data 2011. [cited 2020 Dec 9]. Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf."},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.09.012"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1811271"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.08.017"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2021.1913144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:08:45Z","timestamp":1670544525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2021.1913144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,8,24]]}},"alternative-id":["10.1080\/10428194.2021.1913144"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2021.1913144","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}